We have 3 of 14 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
This study provides a hypothesis-generating framework for future biomarker-guided combination strategies, which requires validation in HER2-positive cohorts and experimental models.
The designed MEV and identified immunogenic targets represent promising vaccine candidates against S. maltophilia, offering safer and more specific therapeutic avenues, and nine novel drug targets were predicted for S. maltophilia, providing new therapeutic insights.
PE/PPE proteins and TCR-recognized immunoreactive peptides are suggested as promising vaccine components against tuberculosis and the designed MEV with the C-terminal fragment of CPE may represent a potential candidate for future development as a mucosal vaccine against M. tuberculosis.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
